S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

ALRN Aileron Therapeutics Inc

2.11

0.00 (0.00%)

Pre Market

Last Updated: 18:00:00

Delayed by 15 minutes

Form ARS - Annual Report to Security Holders

Aileron Therapeutics (NASDAQ:ALRN)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Aileron Therapeutics Charts.

Aileron Therapeutics (NASDAQ:ALRN)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Aileron Therapeutics Charts.

Aileron Therapeutics Inc News

Form 8-K - Current report
Friday 10 January 2025 (1 month ago) • Edgar (US Regulatory)

Aileron Therapeutics Announces Rebranding to Rein Therapeutics
Friday 10 January 2025 (1 month ago) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Monday 9 December 2024 (3 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 6 December 2024 (3 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 6 December 2024 (3 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 6 December 2024 (3 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 4 December 2024 (3 months ago) • Edgar (US Regulatory)

Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Thursday 14 November 2024 (3 months ago) • PR Newswire (US)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Thursday 14 November 2024 (3 months ago) • Edgar (US Regulatory)

Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
Wednesday 13 November 2024 (3 months ago) • PR Newswire (US)

Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma
Thursday 31 October 2024 (4 months ago) • PR Newswire (US)

Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis
Saturday 12 October 2024 (4 months ago) • PR Newswire (US)

More Aileron Therapeutics Inc News Articles

Accredited Solutions (PK)

Northwest Biotherapeutics (QB)

Rennova Health (CE)

Kraig Biocraft Laborator... (QB)

Anavex Life Sciences

North Bay Resources (PK)

Elite Pharmaceuticals (QB)

Bioelectronics (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions